Latest news with #MDAndersonCancerCenter
Globe and Mail
17-06-2025
- Business
- Globe and Mail
Anaplastic Thyroid Cancer Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Anaplastic Thyroid Cancer Pipeline Insight 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). DelveInsight's Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment. The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others. Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others. Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs Anaplastic Thyroid Cancer Emerging Drugs Profile Sapanisertib: Takeda Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models. HLX208: Shanghai Henlius Biotech BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company's proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types. The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment. Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight's detailed report now! @ New Anaplastic Thyroid Cancer Drugs Anaplastic Thyroid Cancer Companies Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others. Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight's expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers Scope of the Anaplastic Thyroid Cancer Pipeline Report Coverage- Global Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others. Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others. Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Anaplastic Thyroid Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Anaplastic Thyroid Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug name: Company name Drug profiles in the detailed report….. Mid Stage Products (Phase II) Sapanisertib: Takeda Drug profiles in the detailed report….. Early Stage Products (Phase I) AIC100: AffyImmune Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Anaplastic Thyroid Cancer Key Companies Anaplastic Thyroid Cancer Key Products Anaplastic Thyroid Cancer- Unmet Needs Anaplastic Thyroid Cancer- Market Drivers and Barriers Anaplastic Thyroid Cancer- Future Perspectives and Conclusion Anaplastic Thyroid Cancer Analyst Views Anaplastic Thyroid Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Medscape
12-06-2025
- Health
- Medscape
Emerging Treatment Strategies Benefit Older Adults With ALL
CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors and poor treatment tolerance. But a variety of treatment approaches beyond chemotherapy-only regimens are making inroads in this challenging disease. That's the message Elias Jabbour, MD, of MD Anderson Cancer Center in Houston, delivered during an educational session at American Society of Clinical Oncology (ASCO) 2025. 'Our data show that 5-year overall survival (OS) for patients aged 65+ years remains less than 20, despite all the treatment advances we've seen in the past decade,' Jabbour told attendees. Referring to a review article he co-authored that was published recently in JAMA Oncology , Jabbour noted that these poorer outcomes are due to both disease characteristics and patient characteristics. Regarding disease characteristics, ALL in older adults is more likely to be of B-cell origin, with a greater co-expression of myeloid antigens. It may also have more adverse cytogenetic abnormalities, including Philadelphia positivity, t(4;11), low hypoploidy/near triploidy. It may also have less high hyperdiploidy, t(12;21), and normal karyotype. These traits make ALL in older adults more refractory to primary chemotherapy, Jabbour said. Patient characteristics that contribute to poorer outcomes in ALL include lower male to female ratio, reduced renal function, and a tendency to have worse mucositis. A history of cardiovascular disease (CVD) is common, Jabbour said, noting the importance of establishing a baseline ejection fraction before beginning treatment. With an estimated past malignancy rate of 8%-16% in this population, these factors all combine to lead to more early deaths, Jabbour added. Jabbour noted that immunotherapies like blinatumomab and inotuzumab have shown promise, with similar response rates in older and younger patients. He summarized results from the trials that established immunotherapy as standard of care in relapsed or refractory ALL. Data published in The New England Journal of Medicine (NEJM) in 2017 showed that the median OS for patients in the blinatumomab group was 7.7 months vs 4.0 months for those in the standard chemotherapy group. More patients had a marrow complete response (CR) in the blinatumomab group than in the chemotherapy group, at 44% vs 25%. Data published in the NEJM in 2016 found that patients who received inotuzumab were more likely to have a marrow CR than those in the chemotherapy group (74% vs 31%). Jabbour also shared data from two studies that stratified patients by age. With blinatumomab, the overall response rate (ORR) was 56% in patients aged 65 years or older compared with 46% in patients younger than 65 years, according to data published in Cancer. Jabbour also shared data from one of his own trials published in Cancer that found that inotuzumab had an ORR of 81% in patients aged 55 years or older vs 80% in those younger than 55 years. 'Then, we asked if we could take these drugs to the frontline and spare the need for intensive chemotherapy for older patients and those with comorbidities,' Jabbour said. 'In 2010, we designed the mini-hyper-CVD regimen with significantly trimmed chemotherapy, then added inotuzumab. Subsequently we added blinatumomab as a consolidation approach and the 10-year follow-up data looked good.' Jabbour shared a list of seven teams of researchers currently testing frontline blinatumomab and inotuzumab combinations in newly diagnosed ALL in older adults. 'All are reporting promising results compared to historical data,' he said. 'We've made progress and survival of older patients is approaching 50% where historically were at 20% overall survival.' The next frontier has been to remove chemotherapy altogether, Jabbour said. 'As investigators, we have to make every effort to move into a chemotherapy-free approach for these vulnerable patients.' This chemotherapy-free approach combining blinatumomab and inotuzumab with TKIs has yielded encouraging results, Jabbour said. 'We know immunotherapies are better than chemotherapy; therefore, it's time to combine them with TKIs,' he said. 'We must prevent central nervous system (CNS) relapses because patients are living longer, and these CNS relapses are what's limiting our progress.' Jabbour highlighted the TKI ponatinib, noting that his and other groups have shown that the use of ponatinib has increased minimal residual disease (MRD)-negative CRs, as well as significantly increasing event-free survival. Ongoing trials are evaluating further optimizations, including integrating CAR T-cell therapy. 'We are measuring MRD by next-generation sequencing (NGS) at 10-6. If a patient is NGS MRD-negative, then we maintain the TKI and do not go for transplant,' Jabbour said. 'In patients who are NGS MRD-positive, we are offering them CAR T cells. If they become MRD-negative, we maintain the TKI; otherwise, we go for transplant.' That means, Jabbour said, that ALL has gone from a disease where transplant was the only way to cure patients to potentially being able to offer CAR T and the promise of finite therapy to these patients. 'We are walking away from chemotherapy because the combination of blinatumomab and a TKI are inducing survival at 4 years of 80%-90%,' he said. 'Moving forward, it's time to integrate immunotherapy fully into the frontline setting, along with bispecific antibody-drug conjugates and CAR T cells.' Jabbour noted that randomized studies are ongoing, with results expected by 2027. 'I hope we will then have a new standard of care for these patients,' he later told Medscape Medical News . Jabbour disclosed having relationships with AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Astellas Pharma, Bristol Myers Squibb, Genentech, Incyte, Pfizer, and Takeda.
Arab Times
24-05-2025
- Health
- Arab Times
Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests
NEW YORK, May 24, (AP): Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity. "This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,' said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study. The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine. "Chronic disease and chronic disease prevention are some of my passions,' said Mavromatis, a former research fellow with an NIH training program. GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain. In the study, researchers analyzed data from 43 U.S. health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics. After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group. The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.
Associated Press
30-04-2025
- Health
- Associated Press
Jointly Funded Research Explores Cutting-Edge RNA Sequencing in Rare Ovarian Cancer
STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer Center to Advance Low-Grade Ovarian Cancer Treatment HOUSTON, TEXAS / ACCESS Newswire / April 30, 2025 / Two patient-driven ovarian cancer nonprofits - STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries - have awarded a $115,580 research grant to Dr. Kwong-Kwok Wong at The University of Texas MD Anderson Cancer Center to investigate new biomarkers that could improve treatment options for patients with low-grade serous ovarian cancer (LGSOC).MD Anderson Cancer Center MD Anderson Cancer Center in Houston, TX is where the ovarian cancer research project with Not These Ovaries is being funded. The research study will utilize long-read RNA sequencing, a cutting-edge technology that allows scientists to examine full-length RNA transcripts in greater detail than previously possible. This technique could identify novel gene fusions and biomarkers that indicate whether a patient will respond to chemotherapy or endocrine therapy - an urgent need in LGSOC, where traditional treatments often show limited effectiveness. 'This pilot project is exploring a promising technology to perform more accurate measurements of transcript activities and discover new genetic markers in low-grade serous ovarian cancer,' said Dr. Wong, principal investigator at MD Anderson. 'As the accuracy of long-read sequencing improves, we are optimistic about the potential in clinical applications for patients who need better options.' Currently, only 20% of LGSOC patients respond to platinum-based chemotherapy, the standard of care for other ovarian cancer types. Patients typically undergo surgery followed by chemotherapy and treatment with aromatase inhibitors, which block estrogen production. However, outcomes remain limited due to the unique biology of LGSOC and the lack of personalized therapies. The study will analyze RNA samples from patients who have and have not responded to chemotherapy or hormone therapy, with the goal of uncovering molecular patterns that could guide treatment decisions and lead to more tailored, effective care. 'This research directly addresses the gap in options for patients with this rare and underfunded cancer,' said Emily Campbell, Executive Director of Not These Ovaries. 'We are proud to invest in innovative science that puts patients at the center of progress.' 'STAAR was founded by LGSOC survivors to drive critical research for a disease that has been overlooked for too long,' said Nicole Andrews, Chair of STAAR. 'We're excited to partner with Not These Ovaries and MD Anderson to accelerate discoveries that could change lives.' About Not These Ovaries Not These Ovaries is dedicated to quickly funding research and trials to eradicate ovarian cancer, with a focus on understudied and underfunded subtypes that primarily affect younger women. Its transparent model ensures 100% of donations fund immediate research and trials, while also empowering patients and families through education and actionable information. About STAAR Low-Grade Serous Ovarian Cancer Foundation STAAR raises critical funds for life-saving research focused on low-grade serous ovarian cancer (LGSOC), a rare and often misunderstood subtype affecting fewer than 10% of ovarian cancer patients. Founded by LGSOC patients, STAAR drives innovation in diagnostics and treatments while collaborating with global research partners to advance care for this community. Contact InformationEmily Campbell Executive Director (786) 814-1700 SOURCE: Not These Ovaries press release
NBC News
30-03-2025
- Health
- NBC News
Katie Thurston confirms her breast cancer is Stage 4
Former 'Bachelorette' Katie Thurston confirmed Friday on Instagram that her breast cancer is Stage 4 and has spread to her liver. In a candid update to viewers, set 43 days after she received a cancer diagnosis, Thurston shared that she has not started treatment yet due to testing and her decision to 'focus on fertility' beforehand. After undergoing a breast ultrasound, mammogram and biopsy of the breast, Thurston said she also had to have a CT scan, bone density scan and MRI. She transferred her care from a hospital in Los Angeles to New York, where she had a PET scan done, which detected spots on her liver that 'were a little suspicious.' 'Unfortunately, I did find out today that my breast cancer has spread to the liver. It is fairly small; however, that does put me at Stage 4,' she said in Friday's video. She shared that her treatment will start April 4 and will involve chemotherapy. 'I know Stage 4 can sound very scary, and it can be. However, given that I am triple positive, and the spots on my liver are fairly small and detected early, I feel very optimistic on my outcome,' she said. Triple-positive refers to a type of breast cancer involving cancerous cells that grow using three different types of receptors, according to a post on the website for the MD Anderson Cancer Center. It's a subtype of HER2 positive breast cancer, which 'is the most treatable type of breast cancer, and it is the most responsive to treatment,' breast medical oncologist Dr. Jason Mouabbi said in the 2023 blog post. Thurston's update comes just days after she married comedian Jeff Arcuri. She went public with her diagnosis on Feb. 15. 'This is day one of sharing and is going to be a long one. This first step of acceptance of my reality was the hardest. But I am ready to fight this,' she said at the time. Thurston first appeared on TV screens as a contestant on 'The Bachelor' in 2021. She then led Season 17 of 'The Bachelorette,' which premiered in June 2021.
